TaiGen Biotechnology
Reports Phase I and Preclinical Data for TG-0054 at the 2009
American Society of Hematology (ASH) Annual Meeting
2009/12/07
More»
Excellent Stem Cell
Mobilization and Safety Profile for TG-0054
2009/09/28
More»
TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
2009/01/20
More»
TaiGen Announces Presentation of Nemonoxacin at the Joint Meeting of ICAAC/IDSA
2008/10/20
More»
TaiGen Announces Positive Data From the Phase II Study of Nemonoxacin (TG-873870) in Community-Acquired Pneumonia
2008/04/07
More»
TaiGen Initiates Phase I Trial of the Stem Cell Mobilizer TG-0054
2008/04/07
More»
|
